Prognostic factors in patients with metastatic or recurrent pancreatic cancer treated with first-line nab -paclitaxel plus gemcitabine: implication of inflammation-based scores

Conclusion Among the inflammation based prognostic scores, mGPS was a reliable prognostic indicator that could stratify survival outcomes in patients with recurrent or mPC who received AG as first-line chemotherapy.
Source: Investigational New Drugs - Category: Drugs & Pharmacology Source Type: research